An interventional study of Yoga 20 minutes and Yoga 60 minutes in Atrial Fibrillation (AF), Atrial Fibrillation (Paroxysmal) and Quality of Life, sponsored by Herlev and Gentofte Hospital. Recruiting at 1 site in Denmark. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by Herlev and Gentofte Hospital · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 176 studies in Atrial Fibrillation with a site in Denmark — 31 open to participants now, 48 under way, 3 of them phase 3. Atrial Fibrillation · Denmark.
Among the 176 studies in Atrial Fibrillation with a site in Denmark, this one is the 59th largest by planned enrollment of the 140 interventional ones that give a count, is one of 7 that started in 2025, is one of 73 with no phase, reaches primary completion later than 25 of the 47 other live ones, and was the 164th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →31 of the 176 studies in Atrial Fibrillation with a site in Denmark are open now. Recruiting first, the newest first:
University College Copenhagen · Sites in Denmark
Ages 18+
Abbott Medical Devices · Sites in Denmark, Belgium, Czechia and 7 more countries
Ages 18+
Acesion Pharma · Sites in Denmark, Bulgaria, Germany and 5 more countries
Ages 18+
University of L'Aquila · Sites in Denmark, Croatia, Egypt and 12 more countries
Ages 18+
Herlev and Gentofte Hospital · Sites in Denmark
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
176 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 17 · Phase 3 32 · Phase 4 19
First in 1999; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 456 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 273 across the 140 interventional studies, 391 across the 36 observational. Of the 118 that completed or were terminated, 40 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
81 of 176 have an industry lead sponsor. The 10 most frequent:
Herlev and Gentofte Hospital is the lead sponsor of 75 studies on the registry; 25 are open to participants now.
Herlev and Gentofte Hospital has 5 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
15 of the studies in Atrial Fibrillation with a site in Denmark that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT07429214Biosense Webster, Inc.A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF | 2026-12-30 |
| NCT07428564Biosense Webster, Inc.A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE PRO Software in Participants With PsAF | 2026-12-30 |
| NCT05104658Center for Clinical Research and PreventionHeart Rehabilitation for All | 2026-12-31 |
| NCT03862859Nicholas CarlsonThe Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis | 2027-01 |
Add all 15 to your calendar (.ics) → With an account.
Among the 176 studies in Atrial Fibrillation with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Atrial fibrillation (AF) is the most common cardiac arrythmia, associated with increased risk of stroke, heart failure, reduced quality of life (QoL), and psychological distress. This randomized controlled trial investigates the effect of MediYoga - a program incorporating deep breathing, low-intensity yoga, and meditation- on disease-specific QoL, blood pressure, and heart rate in 456 patients with paroxysmal AF. With a strong focus on sustainability, the study is fully digital: participants are recruited online, and the 12-week intervention is delivered through an application to smartphone. Additionally, the participants receive online support via Teams. Data will be collected at baseline, 3, 6, and 12 months. The primary outcome is disease specific QoL; secondary outcomes include blood pressure, heart rate, generic QoL, and psychological wellbeing.
Qualitative interviews will explore patients' experiences with the intervention.
Atrial fibrillation (AF) is the most common cardiac arrythmia, affecting approximately 3% of the adult population. AF is associated with substantial morbidity including increased risk of stroke and heart failure, and increased mortality risk. The risk of developing AF raises with age hence the prevalence of AF is expected to increase substantially in the future, due to increased average life expectancy. The costs from diagnostics, treatments, and in- and out-patient care, is likewise estimated to increase, because of the expanding proportion of old-er individuals, development of treatment options, and intensifying search for undiagnosed AF. Risk factors such as hypertension, coronary artery disease, obesity, type 2 diabetes, stress, alcohol overconsumption, smoking, and sleep apnea are also increasing in prevalence and are potent contributors to the development and progression of AF.
Various symptoms can occur during an AF episode, including dizziness, heart palpitations, chest pain, and fatigue. Standard treatment of AF include rhythm- and/or rate-control medications, electrical cardioversion, and in some cases catheter ablation. The treatment focuses on re-ducing symptoms and improving quality of life (QoL).
AF episodes can have negative impact on patient's physical and mental health, as well as so-cial life. Individuals with AF often report poorer QoL, and experience symptoms of stress, depression, and anxiety. Guidelines recommend self-care programs that reduce symptoms and enhance QoL and recommends regularly physical activity to improve overall cardiovascular health. Yoga has been shown to improve health-related quality of life (HRQoL), reduce blood pressure and heart rate, and reduce AF episodes in small studies in-cluding individuals with paroxysmal AF. MediYoga originates from Kundalini Yoga, and is based on deep breathing, combined with slow movements, meditation, and relaxation exercises. MediYoga is designed so that many of the exercises can be performed while seated.
The increasing proportion of older individuals living with AF, demands new ways of organizing and implement rehabilitation for patients. Tele-health, defined as the delivery of health-related services through digital communication technologies is eligible to provide yoga classes at home. Online interventions might increase the likelihood that participants complete the program, as it can be done in their own surroundings without required transportation. Remote recruitment has increasing potential, as it enhances the possibility to include participants from rural districts, who might not participate in onsite rehabilitation, due to the long distance to a rehabilitation center.
To our knowledge, this study is the first study to investigate the effect of an online yoga intervention for patients with symptomatic paroxysmal AF, using a complete online recruitment and implementation strategy.
This study is designed as a randomized controlled digital trial, and will be conducted as an international study with recruitment in both Denmark and Sweden. This study will be conducted as a parallel study with the Swedish study. No data will be transferred. The analyzes will be done separately but published in the same publication with comparisons between countries.
The study is designed as a three arm, randomized superiority trial. Participants will be randomly assigned to one of two groups (1:1) (I) control group including treatment as usual (TAU) alone, or (II) intervention group, in which participants will be allocated to one of two groups, based on their personal preferences; (IIa) performing yoga three times a week for 20 min or (IIb) performing yoga once a week for 60 minutes, for at total of 12 weeks, in addition to TAU
To explore how participants experience being a part of the study, 12-15 patients from each intervention group will be interviewed using qualitative methods. A semi-structured interview guide will be developed through the intervention period, as interesting themes arises. Questions will be formulated to both capture patients experience of the recruitment process and being a part of a study using health technology and remote participation, as well as how the patients experience carrying out the intervention using an app and being in their home. Data will be analyzed using thematic analysis.
All data are self-reported by participants; therefore, access to patient records is not required.
The primary outcome is the disease-specific questionnaire, ASTA. The validated form is divided into three parts: evaluation of the most recent episode of arrythmia and current medication assessment of symptom burden, including a 9-point symptom scale (ASTA symp-tom scale) with a 4-point response scale, and assessment of the HRQoL using a 13-point scale (ASTA scale) with the same 4-point response scale as the symptom scale. The ASTA scale is further divided into a physical and a mental subscale. Scores range from 0 to 100, with higher scores reflecting a higher symptom burden and a worse impact on HRQoL due to arrythmia.
The SF-36 is a standardized, validated, and reliable general HRQoL questionnaire containing 36 items.The items are divided into eight domains and two component summary scales reflecting physical and mental health re-spectively. The two summary scales are analysed on a 0-100 scale, where 100 represents the best possible HRQoL.
HADS is a reliable and validated instrument for screening for clinically relevant symptoms of anxiety and depression in patients. The scale consists of 14 items assessing how patients felt during the previous week. Patients must answer every question in a 4-point Likert scale from 0 to 3. Seven of the items assess the level of depression, and the remaining seven the level of anxiety. Scores are summarized separately for anxiety and depression, resulting in two scores with a range of 0-21. Higher scores indicate more symptoms of anxiety and depression.
In addition to the self-administrated questionnaires, Participants in both the intervention and control groups will be asked to measure their blood pressure and heart rate using a device provided by the research team. They will receive a detailed guide on how to perform these measurements at home, in accordance with the European Guidelines for the Management of Elevated Blood Pressure and Hypertension. Participants will be instructed to take their measurements in the morning, prior to breakfast and any medication intake. Additionally, they will be asked to empty their bladder, refrain from smoking for at least 30 minutes beforehand, and rest for 1-5 minutes before beginning. Blood pressure and heart rate should be measured three times, with 1-2 minutes between each reading. Participants will complete questionnaires and perform blood pressure and heart rate measurements at baseline, 3 and 6 months follow-up.
Sociodemographic characteristics including age, sex, occupational status, educational level, marital status, medication, and comorbidities will be collected via self-report at baseline.
Statistical Analysis Comparisons between the intervention and control groups will be made using Chi-square tests for proportions and repeated measures ANOVA for analyzing questionnaires, blood pressure, and heart rate. Student's t-test will be used for within-group anal-yses. Analysis of covariance (ANCOVA) will be used if a statistically significant relationship is shown between groups regarding demographic data. Drop-out rate will be registered in a flowchart and both per protocol and intent-to-treat analyses will be performed. The level of significance is set at p\<0.05. The analysis will be performed by a blinded statistician.
If the intervention proves effective, the findings could contribute to a scalable, evidence-based model for remote AF rehabilitation, supporting the broader movement toward digital and patient-centered care in cardiology.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Behavioral: Yoga 20 minutes
Behavioral: Yoga 60 minutes
Treatment as usual
The intervention consists of 60 minutes of weekly MediYoga over a 12-week period. Participants in the intervention group may choose whether they prefer to practice yoga for 20 minutes three times per week, or for 60 minutes once per week. The yoga sessions are delivered via a smartphone application, guiding participants through the sessions with both video and audio. In addition, participants are required to complete three questionnaires and measure blood pressure and heart rate at baseline, and at 3 and 6 months of follow-up.
Also known as: MediYoga, MOSI
The intervention consists of 60 minutes of weekly MediYoga over a 12-week period. Participants in the intervention group may choose whether they prefer to practice yoga for 20 minutes three times per week, or for 60 minutes once per week. The yoga sessions are delivered via a smartphone application, guiding participants through the sessions with both video and audio. In addition, participants are required to complete three questionnaires and measure blood pressure and heart rate at baseline, and at 3 and 6 months of follow-up.
Also known as: MediYoga, MOSI
Arrythmia-Specific Symptoms and Health-Related Quality
The validated form is divided into three parts: (1) evaluation of the most recent episode of arrythmia and current medication (2) assessment of symptom burden, including a 9-point symptom scale (ASTA symptom scale) with a 4-point response scale, and (3) assessment of the HRQoL using a 13-point scale (ASTA scale) with the same 4-point response scale as the symptom scale. The ASTA scale is further divided into a physical and a mental subscale. Scores range from 0 to 100, with higher scores reflecting a higher symptom burden and a worse impact on HRQoL due to arrythmia
Time frame: Baseline, and at 3 and 6 months after enrollment
Health-Related Quality of Life
The SF-36 is a standardized, validated, and reliable general HRQoL questionnaire containing 36 items. The questionnaire is commonly used in AF studies. The items are divided into eight domains and two component summary scales reflecting physical and mental health re-spectively. The two summary scales are analysed on a 0-100 scale, where 100 represents the best possible HRQoL.
Time frame: Baseline, and at 3 and 6 months after enrollment
Mental health
HADS is a reliable and validated instrument for screening for clinically relevant symptoms of anxiety and depression in patients. The scale consists of 14 items assessing how patients felt during the previous week. Patients must answer every question in a 4-point Likert scale from 0 to 3. Seven of the items assess the level of depression, and the remaining seven the level of anxiety. Scores are summarized separately for anxiety and depression, resulting in two scores with a range of 0-21. Higher scores indicate more symptoms of anxiety and depression
Time frame: Baseline, and at 3 and 6 months after enrollment
Blood pressure
Blood pressure
Time frame: Baseline, and at 3 and 6 months after enrollment
Pulse
Pulse monitoring
Time frame: At baseline, and 3 and 6 months after enrollment
Plan to share: Yes — Data will be shared upon reasonable request
Supporting information: Study protocol, Informed consent form
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Jun 2027, 21 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 21 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Herlev and Gentofte Hospital